Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Apr 11:10:766.
doi: 10.3389/fimmu.2019.00766. eCollection 2019.

Personalized Dendritic Cell Vaccines-Recent Breakthroughs and Encouraging Clinical Results

Beatris Mastelic-Gavillet  1 , Klara Balint  1 , Caroline Boudousquie  1 , Philippe O Gannon  1 , Lana E Kandalaft  1
Affiliations
Review

Personalized Dendritic Cell Vaccines-Recent Breakthroughs and Encouraging Clinical Results

Beatris Mastelic-Gavillet et al. Front Immunol. .

Abstract

With the advent of combined immunotherapies, personalized dendritic cell (DC)-based vaccination could integrate the current standard of care for the treatment of a large variety of tumors. Due to their proficiency at antigen presentation, DC are key coordinators of the innate and adaptive immune system, and have critical roles in the induction of antitumor immunity. However, despite proven immunogenicity and favorable safety profiles, DC-based immunotherapies have not succeeded at inducing significant objective clinical responses. Emerging data suggest that the combination of DC-based vaccination with other cancer therapies may fully unleash the potential of DC-based cancer vaccines and improve patient survival. In this review, we discuss the recent efforts to develop innovative personalized DC-based vaccines and their use in combined therapies, with a particular focus on ovarian cancer and the promising results of mutanome-based personalized immunotherapies.

Keywords: cancer; dendritic cells; immunotherapy; neo-antigens; vaccines.

PubMed Disclaimer

References

    1. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. (1998) 392:245–52. 10.1038/32588 - DOI - PubMed
    1. Gallo PM, Gallucci S. The dendritic cell response to classic, emerging, and homeostatic danger signals. Implications for autoimmunity. Front Immunol. (2013) 4:138. 10.3389/fimmu.2013.00138 - DOI - PMC - PubMed
    1. Nace G, Evankovich J, Eid R, Tsung A. Dendritic cells and damage-associated molecular patterns: endogenous danger signals linking innate and adaptive immunity. J Innate Immun. (2012) 4:6–15. 10.1159/000334245 - DOI - PubMed
    1. Bonasio R, von Andrian UH. Generation, migration and function of circulating dendritic cells. Curr Opin Immunol. (2006) 18:503–11. 10.1016/j.coi.2006.05.011 - DOI - PubMed
    1. Bloy N, Pol J, Aranda F, Eggermont A, Cremer I, Fridman WH, et al. Trial watch: dendritic cell-based anticancer therapy. Oncoimmunology. (2014) 3:e963424. 10.4161/21624011.2014.963424 - DOI - PMC - PubMed

Publication types

Substances

LinkOut - more resources